Phase II randomized, double-blind, placebo-controlled study of whole-brain irradiation with concomitant chloroquine for brain metastases

Table 1 Patient characteristics

Characteristic	CLQ arm	Control arm	p^§
	n = 39	n = 34
Gender
Male	11(28.2%)	9 (14.7%)
Female	28 (71.8%)	25 (85.3%)	0.868
Age (median)	55.7 ± 13	52 ± 10.6
Range
<55	18 (46.1)	21 (61.8.8%)	0.182
≥55	21 (53.91.8%)	13 (38.2.2%)
KPS
<80	8 (20.5%)	6 (17.6%)	0.756
≥80	31 (79.5%)	28 (82.4%)
No. metastases
<4	28 (71.8%)	22 (64.7%)	0.564
≥4	11 (28.2%)	12 (35.3%)
Histology
NSCLC and others	33 (84.6%)	25 (73.54%)	0.242
Breast cancer	6 (15.4%)	9 (26.5%)
RPA
I	1 (2.5%)	2 (5.9%)	0.476
II	38 (97.5%)	32 (94.1%)
Time of brain metastasis
During primary tumor diagnosis	23 (58.9%)	19 (55.9%)	0.816
Recurrence or progression	16 (41.151.6%)	15 (44.1%)

Abbreviations: CLQ chloroquine, KPS Karnofsky performance score, NSCLC non-small-cell-lung cancer, RPA recursive partitioning analysis, CHT chemotherapy. ^§Person Chi square test.

ISSN: 1748-717X